Actively Recruiting

Age: 18Years +
All Genders
NCT05347732

Predictors of Failed Thrombolysis in Acute Myocardial Infarction

Led by Oslo University Hospital · Updated on 2023-03-23

200

Participants Needed

1

Research Sites

662 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this observational study is to assess why thrombolytic treatment with tissue-plasminogen activator (t-PA) fails in patients with acute ST-segment elevation myocardial infarction (STEMI). The study will include 200 STEMI patients at the time of arrival at Oslo University Hospital Ullevål after receiving prehospital thrombolysis. A blood sample will be taken immediately for the study of factors related to coagulation, fibrinolysis and inflammation. Levels of the biomarkers will be compared between patients with successful and failed thrombolysis.

CONDITIONS

Official Title

Predictors of Failed Thrombolysis in Acute Myocardial Infarction

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • STEMI patients > 18 years given prehospital thrombolysis.
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Oslo University Hospital

Oslo, Norway

Actively Recruiting

Loading map...

Research Team

R

Ragnhild Helseth, MD PhD

CONTACT

K

Kristine Kindberg, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here